Shares in Intersect ENT (NSDQ:XENT) have fallen slightly today despite the medical device maker releasing fourth quarter and full year 2018 earnings that met consensus expectations from analysts on Wall Street. The Menlo Park, Calif.-based company posted losses of $5 million, or 16¢ per share, on sales of approximately $32.8 million for the three months ended […]
Intersect ENT Inc.
Dexcom Q4 prelims top consensus | Wall Street Beat
Dexcom (NSDQ:DXCM) topped estimates on Wall Street today with preliminary results for its fourth-quarter financial results. The San Diego, Calif.-based company said it expects to report $331 million in sales for the quarter ended Dec. 31 – up at least 50% from the same period last year. For the full year of 2018, Dexcom is slated […]
Intersect ENT launches trial of drug-coated sinus balloon
Intersect ENT (NSDQ:XENT) said today that it enrolled the first patient in a trial of its Ascend drug-coated sinus balloon. The Menlo Park, Calif.-based company’s device is designed to deliver mometasone furoate directly to a person’s sinuses at the time of dilation. The 70-person study is slated to explore whether the Ascend device can reduce inflammation […]
Intersect ENT touts pooled analysis of steroid-releasing sinus implants
Intersect ENT (NSDQ:XENT) last week touted the publication of a pooled analysis of the company’s Propel Contour and Propel Mini steroid-eluting sinus implants. The company’s devices are designed to prop open the sinus ostia following endoscopic sinus surgery. As the implant dissolves, medicine is delivered directly to the sinus lining. The analysis, published in the International Forum […]
Intersect ENT tops estimates with Q3 results
Shares in Intersect ENT (NSDQ:XENT) fell today even though the medical device maker topped expectations on Wall Street with its third-quarter financial results. The Menlo Park, Calif.-based company posted a net loss of -$7.6 million on sales of $24.7 million for the 3 months ended Sept. 30, for sales growth of 11% compared with the same period […]
Anthem adds Intersect ENT’s Sinuva implant to formulary
Anthem this month added Intersect ENT‘s (NSDQ:XENT) Sinuva steroid-releasing implant to its updated formulary as a Tier 3 product, according to a note from Leerink analysts. The product is designated on Anthem’s formulary as “LD” – limited distribution – and is only available to certain pharmacies or wholesalers. Intersect ENT launched the product in the […]
Intersect ENT shares tumble on Q2 results
Shares in Intersect ENT (NSDQ:XENT) fell today after the medical device maker missed sales expectations on Wall Street with its second-quarter financial results. The Menlo Park, Calif.-based company posted a net loss of -$4.2 million on sales of $26.3 million for the 3 months ended June 30, for sales growth of 9.7% compared with the same […]
Intersect ENT beats The Street with Q1 sales, earnings
Shares in Intersect ENT (NSDQ:XENT) held steady today after the medical device maker topped expectations on Wall Street with its first-quarter results. The Menlo Park, Calif.-based company posted a net loss of -$6.1 million, or -21¢ per share, on sales of $24.7 million for the 3 months ended March 31, for bottom-line growth of 8.8% on […]
Intersect ENT launches Sinuva steroid-releasing sinus implant
Intersect ENT (NSDQ:XENT) launched its steroid-releasing sinus implant, Sinuva, in the U.S. today. The company’s drug-eluting device is designed to treat nasal polyp disease in patients who have undergone previous sinus surgery. Sinuva is placed during a routine doctor’s office visit and releases an anti-inflammatory steroid, mometasone furoate, directly to the patient’s nasal polyps for up to […]
Intersect ENT posts Street-beating Q4, full-year sales, earnings
Shares in Intersect ENT (NSDQ:XENT) rose today after the medical device maker topped expectations on Wall Street with its fourth quarter and full-year financial results. The Menlo Park, Calif.-based company posted a net loss of -$3.2 million, or-11¢ per share, on sales of $29.5 million for the three months ended Dec. 31, for sales growth of […]
